Hinova Pharmaceuticals (SH:688302) Xin Lang Cai Jing·2025-08-29 02:06Group 1 - The core viewpoint of the news is that Haichuang Pharmaceutical has shown significant trading activity and financial performance, with a notable increase in revenue and changes in shareholder structure [1][2]. Group 2 - On August 28, Haichuang Pharmaceutical's stock price decreased by 0.61%, with a trading volume of 176 million yuan. The financing buy-in amount was 15.64 million yuan, while the financing repayment was 13.19 million yuan, resulting in a net financing buy-in of 2.45 million yuan [1]. - As of August 28, the total balance of margin trading for Haichuang Pharmaceutical was 329 million yuan, accounting for 6.94% of its market capitalization, which is above the 90th percentile level over the past year [1]. - The company has not engaged in any short selling activities on August 28, with a short selling balance of 0 shares, indicating a high level of confidence among investors [1]. Group 3 - As of June 30, the number of shareholders for Haichuang Pharmaceutical increased to 6,555, up by 56.33%, while the average circulating shares per person decreased by 28.30% to 12,435 shares [2]. - For the first half of 2025, Haichuang Pharmaceutical reported a revenue of 13.17 million yuan, representing a year-on-year growth of 11,899.08%. However, the net profit attributable to the parent company was -61.85 million yuan, which is a 38.40% increase compared to the previous period [2]. - Among the top ten circulating shareholders, Penghua Medical Technology Stock A (001230) is the second largest shareholder, holding 3.64 million shares, which is a decrease of 119,500 shares from the previous period [2].